The population structure of Staphylococcus aureus in China and Europe assessed by multiple-locus variable number tandem repeat analysis; clues to geographical origins of emergence and dissemination

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
X YanH Grundmann

Abstract

To compare the genetic population structure of Staphylococcus aureus from China and Europe, 1294 human isolates were characterized by multiple-locus variable number tandem repeat analysis (MLVA). In total, MLVA identified 17 MLVA complexes (MCs), comprising 260 MLVA types (MTs) among the Chinese isolates and 372 MTs among the European isolates. The five most frequent MCs among the Chinese isolates belonged to MC398, MC5 subclade a, MC8, MC437 and MC7 and made up 55% of the sample. For the European isolates, the five most frequent MCs consisted of MC5 subclade a, MC45, MC8, MC30 and MC22, which accounted for 64% of the sample. Phylogeographic analysis of the major MCs shared between China and Europe points to a European origin of MC8 but cannot provide a consistent signal for MC5 subclade a, probably indicating a different origin. Diversity and frequency distributions of other lineages were also compared. Altogether, this study provides the first snapshot of two extant populations of S. aureus from Europe and China, and important clues on the emergence and dissemination of different lineages of S. aureus.

References

Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Jan 4, 2001·The New England Journal of Medicine·C von EiffG Peters
May 20, 2003·Journal of Bacteriology·Edward J FeilNicholas P J Day
Jul 17, 2004·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·R MatoH de Lencastre
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Feb 3, 2006·Functional & Integrative Genomics·Jodi A Lindsay, Matthew T G Holden
Sep 6, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ulrich NübelMark Achtman
Oct 9, 2009·International Journal of Medical Microbiology : IJMM·Jodi A Lindsay
Jan 20, 2010·PLoS Medicine·Hajo GrundmannUNKNOWN European Staphylococcal Reference Laboratory Working Group
Jan 23, 2010·Science·Simon R HarrisStephen D Bentley
Sep 24, 2010·Journal of the Royal Society, Interface·Martin C J BootsmaMarc J M Bonten
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Jae-Hoon SongUNKNOWN ANSORP Study Group
Aug 23, 2012·Journal of Infection in Developing Countries·Nyambura MoremiHeike Claus
Jan 15, 2014·International Journal of Medical Microbiology : IJMM·Xiaomei YanJianzhong Zhang
Feb 7, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C GlasnerJ M van Dijl

❮ Previous
Next ❯

Citations

Sep 18, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S McNicholasD Fitzgerald-Hughes
Dec 19, 2020·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Anita BlomfeldtHege Vangstein Aamot

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.